Ridderstråle M, et al. - Researchers reported 208-week data from a masked randomized controlled trial (the EMPA-REG H2H-SU trial) comparing empagliflozin with glimepiride in metformin-treated patients with type 2 diabetes. Patients with type 2 diabetes displayed reduced HbA_1c with a significantly lower risk of hypoglycemia in association with empagliflozin 25 mg as add-on to metformin for 208 weeks. Furthermore, with empagliflozin 25 mg as add-on to metformin, a significantly smaller proportion of patients required rescue therapy vs glimepiride.